Get access

Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis

Authors

  • Veronika Válková,

    Corresponding author
    1. Institute of Experimental Haematology, First Faculty of Medicine, Charles University, Prague, Czech Rep
    • Department of Bone Marrow Transplantation, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    Search for more papers by this author
  • Jaroslav Polák,

    1. Department of Molecular Biology, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    Search for more papers by this author
  • Marketa Marková,

    1. Department of Bone Marrow Transplantation, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    2. Institute of Experimental Haematology, First Faculty of Medicine, Charles University, Prague, Czech Rep
    Search for more papers by this author
  • Antonin Vítek,

    1. Department of Bone Marrow Transplantation, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    2. Institute of Experimental Haematology, First Faculty of Medicine, Charles University, Prague, Czech Rep
    Search for more papers by this author
  • Hana Hájková,

    1. Department of Molecular Biology, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    Search for more papers by this author
  • Cyril Šálek,

    1. Department of Bone Marrow Transplantation, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    2. Institute of Experimental Haematology, First Faculty of Medicine, Charles University, Prague, Czech Rep
    Search for more papers by this author
  • Bohumil Procházka,

    1. Department of Biostatistics, University Hospital, Third Faculty of Medicine, Charles University, Prague, Czech Rep
    Search for more papers by this author
  • Petr Cetkovský,

    1. Department of Bone Marrow Transplantation, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    2. Institute of Experimental Haematology, First Faculty of Medicine, Charles University, Prague, Czech Rep
    Search for more papers by this author
  • Marek Trněný

    1. Department of Bone Marrow Transplantation, Institute of Haematology and Blood Transfusion, Prague, Czech Rep
    2. Institute of Experimental Haematology, First Faculty of Medicine, Charles University, Prague, Czech Rep
    Search for more papers by this author

  • Conflict of interest: None.

Corresponding author: Veronika Válková, MD, PhD, Department of Bone Marrow Transplantaion, Institute of Haematology and Blood Transfusion and Institute of Experimental Haematology, First Faculty of Medicine, Charles University, U nemocnice 1, Prague, 12800, Czech Republic.

Tel.: +420 221 977 319;fax: +420 221 977 360; e-mail: veronika.valkova@uhkt.cz

Abstract

Overall 42 patients (pts) transplanted in hematological CR1 were retrospectively analyzed. Median follow-up was 15 months (range 2–77). The expression of WT1 gene was measured according to the European Leukaemia Net recommendations. At the time of allogeneic stem cell transplantation (allo-SCT) 29 pts were WT1-negative and 13 pts were WT1-positive. In the univariate analysis, significantly better results were observed in the group of WT1 neg in terms of progression-free survival (in three yr 77% vs. 27%, p = 0.001). In multivariate analysis, the only significant feature in terms of better OS was WT1 negativity (p = 0.029). Our results show that minimal residual disease status measured by quantitative assessment of WT1 gene in acute myeloid leukemia pts in CR1 significantly affects their future prognosis after allo-SCT.

Get access to the full text of this article

Ancillary